Should I buy or sell Vistagen Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTGN shares. View VTGN analyst ratings or view top-rated stocks .

What is Vistagen Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price objectives for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 304.3% from the stock's current price. View analysts price targets for VTGN or view top-rated stocks among Wall Street analysts .

How have VTGN shares performed in 2024?

Vistagen Therapeutics' stock was trading at $5.14 at the beginning of 2024. Since then, VTGN stock has decreased by 8.6% and is now trading at $4.70. View the best growth stocks for 2024 here .

When is Vistagen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our VTGN earnings forecast .

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) issued its earnings results on Tuesday, February, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.09. The company had revenue of $0.41 million for the quarter, compared to analysts' expectations of $0.73 million. Vistagen Therapeutics had a negative trailing twelve-month return on equity of 72.10% and a negative net margin of 3,073.51%.

What ETF holds Vistagen Therapeutics' stock?

AdvisorShares Psychedelics ETF holds 74,201 shares of VTGN stock, representing 5.21% of its portfolio.

When did Vistagen Therapeutics' stock split?

Vistagen Therapeutics's stock reverse split before market open on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ) , AK Steel (AKS) , Ayala Pharmaceuticals (ADXS) , Matinas BioPharma (MTNB) , Rite Aid (RAD) , Sorrento Therapeutics (SRNE) , Lithium Americas (LAC) , ImmunoGen (IMGN) , Yamana Gold (AUY) and CRISPR Therapeutics (CRSP) .

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VTGN

Vistagen Therapeutics (VTGN) Stock Price, News & Analysis

→ This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad)

Free VTGN Stock Alerts

$4.70

+0.03 (+0.64%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.60
▼
$4.82
50-Day Range: $3.92
▼
$5.42
52-Week Range: $1.62
▼
$24.71

Volume: 194,426 shs
Average Volume: 286,404 shs
Market Capitalization: $126.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.00

Get Vistagen Therapeutics alerts:

Vistagen Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 304.3% Upside
$19.00 Price Target
Short Interest: Bearish
5.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.56) to ($2.00) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.31 out of 5 stars

Medical Sector

731st out of 918 stocks

Pharmaceutical Preparations Industry

320th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Vistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Vistagen Therapeutics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.27% of the float of Vistagen Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Vistagen Therapeutics has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Vistagen Therapeutics has recently decreased by 3.76%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Vistagen Therapeutics does not currently pay a dividend.
Dividend Growth
Vistagen Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VTGN.

2.0

News and Social Media Coverage

News Sentiment
Vistagen Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Vistagen Therapeutics this week, compared to 2 articles on an average week.
Search Interest
34 people have searched for VTGN on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Vistagen Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vistagen Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.16% of the stock of Vistagen Therapeutics is held by insiders.
Percentage Held by Institutions
78.39% of the stock of Vistagen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Vistagen Therapeutics are expected to decrease in the coming year, from ($1.56) to ($2.00) per share.
Price to Book Value per Share Ratio
Vistagen Therapeutics has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Vistagen Therapeutics Stock (NASDAQ:VTGN)

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

VTGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VTGN Stock News Headlines

April 13, 2024 | americanbankingnews.com

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average of $4.80

April 9, 2024 | investorplace.com

Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 9, 2024 | businesswire.com

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

April 1, 2024 | finance.yahoo.com

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

March 31, 2024 | investorplace.com

Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027

March 28, 2024 | msn.com

PDS Biotechnology GAAP EPS of -$1.39 beats by $0.06

March 26, 2024 | finance.yahoo.com

30 Countries with the Lowest Depression Rates

April 18, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

March 17, 2024 | seekingalpha.com

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

March 16, 2024 | finance.yahoo.com

VTGN Apr 2024 10.000 call

March 15, 2024 | cnbc.com

This overlooked corner of women's health could be a $350 billion market opportunity

March 11, 2024 | businesswire.com

Vistagen to Present at Stifel 2024 Virtual CNS Days

February 28, 2024 | finance.yahoo.com

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

February 28, 2024 | businesswire.com

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

February 22, 2024 | benzinga.com

Vistagen Therapeutics Stock (NASDAQ:VTGN), Short Interest Report

February 21, 2024 | finance.yahoo.com

Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?

February 19, 2024 | investorplace.com

3 Revolutionary Biotech Stocks Poised for 10X Surge

February 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for VistaGen: Promising Clinical Results and Strong Financial Outlook

February 15, 2024 | finance.yahoo.com

Vistagen Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

February 15, 2024 | finance.yahoo.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript

February 14, 2024 | investorplace.com

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

February 13, 2024 | morningstar.com

Vistagen Therapeutics Inc VTGN

February 13, 2024 | benzinga.com

Recap: Vistagen Therapeutics Q3 Earnings

February 13, 2024 | msn.com

Vistagen Therapeutics files for $350M mixed shelf

February 13, 2024 | finance.yahoo.com

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

February 13, 2024 | finance.yahoo.com

Vistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ...

See More Headlines

Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 6/26/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VTGN
CUSIP: N/A
CIK: 1411685
Web: www.vistagen.com
Phone: (650) 577-3600
Fax: 888-482-2602
Employees: 37
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.00
High Stock Price Target: $30.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +304.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,250,000.00
Net Margins: -3,073.51%
Pretax Margin: -3,073.22%
Return on Equity: -72.10%
Return on Assets: -61.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 30.76
Quick Ratio: 30.76

Sales & Book Value

Annual Sales: $1.11 million
Price / Sales: 114.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.65 per share
Price / Book: 2.85

Miscellaneous

Outstanding Shares: 27,020,000
Free Float: 26,171,000
Market Cap: $126.99 million
Optionable: Optionable
Beta: 0.77

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Shawn K. Singh J.D. (Age 61)
CEO & Director
Comp: $600k
Mr. Reid G. Adler Esq. (Age 69)
J.D., Chief Corporate Development Officer & General Counsel
Comp: $371.88k
Ms. Cynthia Lynn Anderson CPA (Age 55)
Chief Financial Officer
Mr. Joshua Prince M.B.A. (Age 54)
Chief Operating Officer
Mr. Mark Adrian McPartland (Age 58)
Senior Vice President of Investor Relations
Comp: $300k
Ms. Trisha Fitzmaurice
Senior Vice President of Human Resources
Dr. Allen Easley Cato III
M.D., Ph.D., Senior Vice President of Development Operations
Dr. Mark J. Ginski Ph.D. (Age 52)
Senior VP and Head of Chemistry, Manufacturing & Controls
Mr. Mark Flather
Senior Vice President of Corporate Strategy & Capital Markets
Dr. Erik Berglund M.D.
Ph.D., Senior VP of Global Regulatory Affairs & Pharmacovigilance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VTGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Vistagen Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTGN shares.
View VTGN analyst ratings or view top-rated stocks.
What is Vistagen Therapeutics' stock price target for 2024?: 4 Wall Street research analysts have issued 12-month price objectives for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 304.3% from the stock's current price.
View analysts price targets for VTGN or view top-rated stocks among Wall Street analysts.
How have VTGN shares performed in 2024?: Vistagen Therapeutics' stock was trading at $5.14 at the beginning of 2024. Since then, VTGN stock has decreased by 8.6% and is now trading at $4.70.
View the best growth stocks for 2024 here.
When is Vistagen Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024.
View our VTGN earnings forecast.
How were Vistagen Therapeutics' earnings last quarter?: Vistagen Therapeutics, Inc. (NASDAQ:VTGN) issued its earnings results on Tuesday, February, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.09. The company had revenue of $0.41 million for the quarter, compared to analysts' expectations of $0.73 million. Vistagen Therapeutics had a negative trailing twelve-month return on equity of 72.10% and a negative net margin of 3,073.51%.

What ETF holds Vistagen Therapeutics' stock?: AdvisorShares Psychedelics ETF holds 74,201 shares of VTGN stock, representing 5.21% of its portfolio.
When did Vistagen Therapeutics' stock split?: Vistagen Therapeutics's stock reverse split before market open on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Vistagen Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Ayala Pharmaceuticals (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).
How do I buy shares of Vistagen Therapeutics?: Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTGN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial